Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of 101BHG-D01 nasal spray for cold-related rhinorrhea
ChiCTR2200065138Phase 2Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 101BHG-D01 in nasopharyngitis and upper respiratory infection (URI) (3 arms), sponsored by Peking University Third Hospital. Primary endpoint: Runny nose symptom severity score (VAS) area under the curve from pre-dose to 96 hours. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
101BHG-D01
03
Conditions
nasopharyngitisupper respiratory infection (URI)
Beyond the preview
Go deeper on ChiCTR2200065138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065138.